Loading stock data…
$87.08-3.45 (-3.81%)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Inhibrx Biosciences, Inc. in the Healthcare sector is trading at $87.08 with a market capitalization of $1.6B. Wall Street consensus targets $266.67 (3 analysts), implying a +206.2% move over the next 12 months. The stock is currently 44% below its 52-week high of $155.29, remaining 4.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $1.30M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$32.15M↓ | -$30.93M | -$30.92M↑ | -$33.81M↓ | -$27.39M |
| Net Income | -$36.65M↓ | -$33.44M↓ | -$32.83M↑ | -$35.26M↓ | -$28.65M |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent t...